



上海源叶生物科技有限公司  
Shanghai yuanye Bio-Technology Co., Ltd  
电话: 021-61312973 传真: 021-55068248  
网址: [www.shyuanye.com](http://www.shyuanye.com)  
邮箱: [shyysw@sina.com](mailto:shyysw@sina.com)

产品名称: **AdipoRon**  
产品别名: **AdipoRon**

生物活性:				
Description	AdipoRon is an orally active adiponectin receptor (AdipoR) agonist, binding to AdipoR1 and AdipoR2 with Kds of 1.8 and 3.1 $\mu$ M, respectively.			
IC <sub>50</sub> & Target	Kd: 1.8 $\mu$ M (AdipoR1), 3.1 $\mu$ M (AdipoR2)[1]			
In Vitro	AdipoRon is an orally active and specific AdipoR agonist, binds to AdipoR1 and AdipoR2, with K <sub>d</sub> s of 1.8 and 3.1 $\mu$ M. AdipoRon (50 nM-50 $\mu$ M) increases AMPK phosphorylation via AdipoR1[1]. AdipoRon (50 $\mu$ M) dose-dependently attenuates the expression of TNF- $\alpha$ and TGF- $\beta$ 1 in the L02 cells. AdipoRon exhibits significant and dosage-dependent growth suppression on macrophages[2]. AdipoRon treatment significantly improves cardiac functional recovery after reperfusion, and inhibits post-MI apoptosis[3]. AdipoRon exerts vasodilation by mechanisms distinct to adiponectin and induces vasorelaxation without a marked decrease in VSMC [Ca <sup>2+</sup> ][4].			
In Vivo	AdipoRon (50 mg/kg, i.v.) causes significant phosphorylation of AMPK in skeletal muscle and liver of wild-type mice but not AdipoR1 <sup>-/-</sup> AdipoR2 <sup>-/-</sup> double-knockout mice[1]. AdipoRon (0.02, 0.1, and 0.5 mg/kg, i.g.) alleviates D-GalN induced hepatotoxicity in mice, and prevents hepatic architecture distortion against D-GalN challenge. The hepatoprotective potential of AdipoRon is particularly evident in higher dosages (0.1 and 0.5 mg/kg)[2]. Enhanced cardiomyocyte apoptosis in APN-deficient mice is rescued by AdipoRon (50 mg/kg, p.o.) administration. Antiapoptotic effect of AdipoRon is attenuated but not lost in AMPK-DN mice[3].			
Solvent&Solubility	<b>In Vitro:</b> DMSO : $\geq$ 44 mg/mL (102.68 mM) H <sub>2</sub> O : < 0.1 mg/mL (insoluble)  * "≥" means soluble, but saturation unknown.			
		Solvent Concentration	Mass	
	Preparing	1 mM	2.3336 mL	11.6681 mL
	Stock Solutions	5 mM	0.4667 mL	2.3336 mL
		10 mM	0.2334 mL	1.1668 mL
	*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液, 一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。 储备液的保存方式和期限: -80°C, 6 months; -20°C, 1 month。-80°C 储存时, 请在 6 个月内使用, -20°C 储存时, 请在 1 个月内使用。 <b>In Vivo:</b> 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液, 再依次添加助溶剂: ——为保证实验结果的可靠性, 澄清的储备液可以根据储存条件, 适当保存; 体内实验的工作液, 建议您现用现配, 当天使用; 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比; 如在配制过程中出现沉淀、析出现象, 可以通过加热和/或超声的方式助溶 1.请依序添加每种溶剂: 10% DMSO→40% PEG300 →5% Tween-80 → 45% saline			



上海源叶生物科技有限公司  
Shanghai yuanye Bio-Technology Co., Ltd  
电话: 021-61312973 传真: 021-55068248  
网址: [www.shyuanye.com](http://www.shyuanye.com)  
邮箱: [shyysw@sina.com](mailto:shyysw@sina.com)

	<p>Solubility: <math>\geq 2.5</math> mg/mL (5.83 mM); Clear solution</p> <p>此方案可获得 <math>\geq 2.5</math> mg/mL (5.83 mM, 饱和度未知) 的澄清溶液。</p> <p>以 1 mL 工作液为例, 取 100 <math>\mu</math>L 25.0 mg/mL 的澄清 DMSO 储备液加到 400 <math>\mu</math>L PEG300 中, 混合均匀向上述体系中加入 50 <math>\mu</math>L Tween-80, 混合均匀; 然后继续加入 450 <math>\mu</math>L 生理盐水定容至 1 mL。</p> <p>2. 请依序添加每种溶剂: 10% DMSO <math>\rightarrow</math> 90% (20% SBE-<math>\beta</math>-CD in saline)</p> <p>Solubility: <math>\geq 2.5</math> mg/mL (5.83 mM); Clear solution</p> <p>此方案可获得 <math>\geq 2.5</math> mg/mL (5.83 mM, 饱和度未知) 的澄清溶液。</p> <p>以 1 mL 工作液为例, 取 100 <math>\mu</math>L 25.0 mg/mL 的澄清 DMSO 储备液加到 900 <math>\mu</math>L 20% 的 SBE-<math>\beta</math>-CD 生理盐水水溶液中, 混合均匀。</p> <p>3. 请依序添加每种溶剂: 10% DMSO <math>\rightarrow</math> 90% corn oil</p> <p>Solubility: <math>\geq 2.5</math> mg/mL (5.83 mM); Clear solution</p> <p>此方案可获得 <math>\geq 2.5</math> mg/mL (5.83 mM, 饱和度未知) 的澄清溶液, 此方案不适用于实验周期在半个月以上的实验。</p> <p>以 1 mL 工作液为例, 取 100 <math>\mu</math>L 25.0 mg/mL 的澄清 DMSO 储备液加到 900 <math>\mu</math>L 玉米油中, 混合均匀。</p>
References	<p>[1]. Okada-Iwabuchi M, et al. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. <i>Nature</i>. 2013 Nov 28;503(7477):493-9.</p> <p>[2]. Wang Y, et al. Hepatoprotective effects of AdipoRon against d-galactosamine-induced liver injury in mice. <i>Eur J Pharm Sci</i>. 2016 Aug 9;93:123-131.</p> <p>[3]. Zhang Y, et al. AdipoRon, the first orally active adiponectin receptor activator, attenuates postischemic myocardial apoptosis through both AMPK-mediated and AMPK-independent signalings. <i>Am J Physiol Endocrinol Metab</i>. 2015 Aug 1;309(3):E275-82.</p> <p>[4]. Hong K, et al. Adiponectin Receptor Agonist, AdipoRon, Causes Vasorelaxation Predominantly Via a Direct Smooth Muscle Action. <i>Microcirculation</i>. 2016 Apr;23(3):207-20.</p>
实验参考:	
Cell Assay	<p>The effects of AdipoRon on the proliferation of parenchymal and non-parenchymal hepatocytes are evaluated in vitro via L02 and RAW264.7, by MTT assay as described with slight modification: 100 <math>\mu</math>L cells suspension (<math>6 \times 10^4</math>/mL) are seeded in a 96-well plate and incubated for 18 h. Fresh media with AdipoRon are added at specified concentrations, and the incubations continue for a further 24 h. Then cells are incubated for 4 h with 0.5 mg/mL of MTT, and analyzed in a microplate reader at 490 nm. Each group is performed in six replications. The mean absorbance values corrected for a blank (medium only) are calculated as percentages of survival[2].</p>
Animal Administration	<p>Mice[2]</p> <p>After 3 days of acclimation, mice are randomly divided into six groups (9 mice in each): control, model, bicyclol (20 mg/kg), AdipoRon (0.02 mg/kg, 0.1 mg/kg, 0.5 mg/kg). The synthetic AdipoRon and bicyclol are dissolved in DMSO and diluted by saline containing 0.5% sodium carboxymethyl cellulose (CMC-Na) [final vehicle: 5% DMSO (v/v) saline solution]. All test groups are administered with vehicle (control and model groups) or therapeutic agents (bicyclol or AdipoRon groups) at a dosing volume of 10 mL/kg, by intragastric (i.g.) gavage twice per day for three consecutive days</p>



上海源叶生物科技有限公司  
Shanghai yuanye Bio-Technology Co., Ltd  
电话: 021-61312973 传真: 021-55068248  
网址: [www.shyuanye.com](http://www.shyuanye.com)  
邮箱: [shyysw@sina.com](mailto:shyysw@sina.com)

	<p>prior to D-GalN administration. 2 h after last treatment, mice are challenged with a single intraperitoneal (i.p.) administration of D-GalN saline solution at a dose of 600 mg/kg to induce acute liver injury, while the control group mice receive saline instead. Then mice are fasted for 20 h before orbital blood collection. Finally, all animals are sacrificed by cervical dislocation, and livers are harvested for biochemical or histopathology analysis[2].</p>
<b>References</b>	<p>[1]. Okada-Iwabu M, et al. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. <i>Nature</i>. 2013 Nov 28;503(7477):493-9.</p> <p>[2]. Wang Y, et al. Hepatoprotective effects of AdipoRon against d-galactosamine-induced liver injury in mice. <i>Eur J Pharm Sci</i>. 2016 Aug 9;93:123-131.</p> <p>[3]. Zhang Y, et al. AdipoRon, the first orally active adiponectin receptor activator, attenuates postischemic myocardial apoptosis through both AMPK-mediated and AMPK-independent signalings. <i>Am J Physiol Endocrinol Metab</i>. 2015 Aug 1;309(3):E275-82.</p> <p>[4]. Hong K, et al. Adiponectin Receptor Agonist, AdipoRon, Causes Vasorelaxation Predominantly Via a Direct Smooth Muscle Action. <i>Microcirculation</i>. 2016 Apr;23(3):207-20.</p>

源叶生物